MedTrace Logo

Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease

NCT01735305 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14032

Last updated 2015-12-11

No results posted yet for this study

Summary

Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.

Conditions

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • Shenyang Northern Hospital

    lead OTHER

Principal Investigators

  • Yaling Han, MD · Shenyang Military Region General Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-12-31
Completion
2015-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01735305 on ClinicalTrials.gov